Edwin Beale

Cellipont Bioservices is a cell therapy CDMO with more than 15 years’ experience in the development and small-to-large batch manufacturing of cell therapies. Our leaders have played an instrumental role in shaping cell therapy development and manufacturing methods and technologies, and our technically-strong team has been recognized by customers and technology partners for its ability to productively grow challenging cells. Cellipont is driven to help our clients to expand patient access to life-changing medicines through best-in-class development, analytical and manufacturing capabilities.   We are a small company with a culture that is extremely responsive and customer-centric. Despite our size, Cellipont Bioservices has very deep technical experience, including 18,000+ tissue samples and more than 900 primary cell cultures. With decades of experience at advanced therapy service companies large and small, our leadership team is guiding Cellipont’s growth with deep knowledge of what it takes succeed in this space.   Cellipont Bioservices facilities and quality systems are GMP-compliant and we hold a California Food & Drug Branch manufacturing license. We have extensive experience in multiple product areas, including CAR-T, iNK, dendritic cell, & other novel cell therapy approaches. OUR NAME: By combining “cell” with the latin root for bridge (pont), the name Cellipont Bioservices reflects several dimensions of what we are all about: we bridge our innovator clients with patients; we bridge technical excellence and personal service; and for our team, we bridge personal passion with professional vocation. As we finalize our corporate rebranding, we look forward to launching a new website in the coming weeks to better share our vision with you.